Small Molecules

29 Aug 2017 Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial
29 Aug 2017 Chi-Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL-689 in Lymphoma Patients in China
29 Aug 2017 AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma
29 Aug 2017 Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease
28 Aug 2017 Bristol-Myers Squibb and Pfizer Present Investigational Eliquis® (apixaban) Data for Patients with Non-Valvular Atrial Fibrillation (NVAF) Undergoing Cardioversion
28 Aug 2017 Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement
28 Aug 2017 European Medicines Agency To Start the Review of The Marketing Authorization Applications for Encorafenib and Binimetinib For the Treatment Of BRAF-Mutant Advanced Melanoma
28 Aug 2017 Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis® (apixaban) Compared to Warfarin in Select High-Risk Patients with Non-Valvular Atrial Fibrillation
28 Aug 2017 Bayer's Xarelto® significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24%
28 Aug 2017 DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial
28 Aug 2017 Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer
25 Aug 2017 Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
25 Aug 2017 European Commission Grants Approval for Mavenclad (Cladribine Tablets)
24 Aug 2017 Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
24 Aug 2017 Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack
24 Aug 2017 Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
23 Aug 2017 Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis
23 Aug 2017 Cancer Research UK launches trial to test new drug in patients with advanced cancer
23 Aug 2017 Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy
23 Aug 2017 Curtana Pharmaceuticals Successfully Completes Pre-IND Submission for CT-179 for the Treatment of Malignant Gliomas
22 Aug 2017 PharmAkea Announces Successful Completion of a Phase 1 Trial in Healthy Subjects For Its Novel LOXL2 Inhibitor, PAT-1251
22 Aug 2017 Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non‑Opioid Pain Management Patch in Bunionectomy Surgery
22 Aug 2017 Lakewood-Amedex Inc. Completes Clinical Trial Recruitment for Final Cohort of the Company's Phase 1/2a Program in Patients with Infected Diabetic Foot Ulcers
22 Aug 2017 First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplant in Patients with FLT3 Mutation-positive Acute Myeloid Leukemia
22 Aug 2017 Cardiome provides U.S. regulatory update for brinavess

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing